(Source: Shire plc) June 29, 2016 Topline results revealed the study met its primary endpoints for both doses of SHP465 (12.5mg and 37.5mg) administered once daily, indicating superiority over placebo in ADHD symptom improvement (p Key secondary endpoint was also met for both doses showing significant improvement over placebo in patients' global functioning (p Study adds to the robust database of now 16 clinical studies enrolling more than 1,600 subjects in SHP465 clinical development program, positioning Shire to file a U.S. FDA resubmission by the end of 2016. Lexington, Mass. - June 29, 2016 - For U.S. Audiences Only - Shire plc (LSE: SHP, NASDAQ: SHPG) today announced positive topline...
↧